Identifying the need for a multidisciplinary approach for early recognition of mucopolysaccharidosis VI (MPS VI)

Autor: Shuan-Pei Lin, Antony Fu, Albert D. Yang, Motomichi Kosuga, Hsiang-Yu Lin, Shanti Balasubramaniam, Teck-Hock Toh, Meow-Keong Thong, Verasak Thamkunanon, Dong-Kyu Jin, Nancy J. Mendelsohn, Kaustuv Bhattacharya, Hasri Samion, Young Hee Kwun, Torayuki Okuyama, Anita Inwood, Ok Hwa Kim, Akemi Tanaka, Adeline Tan, Michael Fietz, Yew Sing Choy, Jim McGill
Rok vydání: 2015
Předmět:
Zdroj: Molecular Genetics and Metabolism. 115:41-47
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2015.03.005
Popis: Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) is caused by deficient activity of the enzyme, N-acetylgalactosamine-4-sulfatase, resulting in impaired degradation of the glycosaminoglycan dermatan sulfate. Patients experience a range of manifestations including joint contractures, short stature, dysostosis multiplex, coarse facial features, decreased pulmonary function, cardiac abnormalities, corneal clouding and shortened life span. Recently, clinicians from institutions in the Asia-Pacific region met to discuss the occurrence and implications of delayed diagnosis and misdiagnosis of MPS VI in the patients they have managed. Eighteen patients (44% female) were diagnosed. The most common sign presented by the patients was bone deformities in 11 patients (65%). Delays to diagnosis occurred due to the lack of or distance to diagnostic facilities for four patients (31%), alternative diagnoses for two patients (15%), and misleading symptoms experienced by two patients (15%). Several patients experienced manifestations that were subtler than would be expected and were subsequently overlooked. Several cases highlighted the unique challenges associated with diagnosing MPS VI from the perspective of different specialties and provide insights into how these patients initially present, which may help to elucidate strategies to improve the diagnosis of MPS VI.
Databáze: OpenAIRE